Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 30 | 2025 | 334 | 13.800 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2023 | 889 | 3.600 |
Why?
|
| Neoplasm, Residual | 10 | 2024 | 181 | 3.540 |
Why?
|
| Dexamethasone | 11 | 2024 | 343 | 2.730 |
Why?
|
| Oligopeptides | 5 | 2024 | 188 | 1.990 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2024 | 2506 | 1.670 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2022 | 91 | 1.480 |
Why?
|
| Antibodies, Monoclonal | 3 | 2025 | 1396 | 1.340 |
Why?
|
| Transplantation, Autologous | 9 | 2023 | 347 | 1.260 |
Why?
|
| Myeloma Proteins | 2 | 2025 | 37 | 1.190 |
Why?
|
| Hematologic Neoplasms | 2 | 2022 | 344 | 1.150 |
Why?
|
| Antibodies, Bispecific | 2 | 2024 | 29 | 1.080 |
Why?
|
| Waldenstrom Macroglobulinemia | 2 | 2024 | 11 | 1.030 |
Why?
|
| Geriatric Assessment | 4 | 2024 | 182 | 1.010 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2022 | 8 | 1.010 |
Why?
|
| Premedication | 1 | 2024 | 57 | 0.940 |
Why?
|
| Humans | 48 | 2025 | 89968 | 0.860 |
Why?
|
| Paraproteinemias | 1 | 2022 | 15 | 0.800 |
Why?
|
| Serotonin and Noradrenaline Reuptake Inhibitors | 1 | 2021 | 1 | 0.780 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2021 | 2 | 0.780 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 281 | 0.730 |
Why?
|
| Middle Aged | 19 | 2025 | 26148 | 0.720 |
Why?
|
| Agammaglobulinemia | 1 | 2020 | 20 | 0.710 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2025 | 197 | 0.710 |
Why?
|
| Aged | 17 | 2025 | 19254 | 0.710 |
Why?
|
| Amyloidosis | 1 | 2022 | 130 | 0.700 |
Why?
|
| Cancer Survivors | 1 | 2021 | 95 | 0.680 |
Why?
|
| Daunorubicin | 1 | 2019 | 78 | 0.670 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 2331 | 0.660 |
Why?
|
| Cytarabine | 1 | 2019 | 219 | 0.640 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 131 | 0.640 |
Why?
|
| Bacterial Infections | 1 | 2020 | 184 | 0.630 |
Why?
|
| Disease Management | 2 | 2020 | 327 | 0.610 |
Why?
|
| Remission Induction | 1 | 2019 | 741 | 0.580 |
Why?
|
| Preoperative Care | 1 | 2019 | 395 | 0.570 |
Why?
|
| Diabetes Insipidus, Nephrogenic | 1 | 2017 | 1 | 0.560 |
Why?
|
| Patient Care Team | 1 | 2019 | 284 | 0.560 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2017 | 11 | 0.560 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 312 | 0.550 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2020 | 799 | 0.540 |
Why?
|
| Male | 17 | 2025 | 42680 | 0.510 |
Why?
|
| Adult | 11 | 2024 | 26822 | 0.510 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2015 | 9 | 0.500 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 539 | 0.500 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 399 | 0.500 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 189 | 0.500 |
Why?
|
| Precision Medicine | 1 | 2019 | 413 | 0.490 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 654 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 608 | 0.480 |
Why?
|
| Aged, 80 and over | 6 | 2024 | 6783 | 0.470 |
Why?
|
| Female | 17 | 2025 | 46594 | 0.470 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1054 | 0.460 |
Why?
|
| Maintenance Chemotherapy | 2 | 2024 | 84 | 0.460 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2025 | 78 | 0.420 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 855 | 0.420 |
Why?
|
| Physicians | 1 | 2020 | 692 | 0.410 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 256 | 0.400 |
Why?
|
| Consensus | 2 | 2024 | 366 | 0.400 |
Why?
|
| Flow Cytometry | 2 | 2024 | 690 | 0.350 |
Why?
|
| T-Lymphocytes | 3 | 2024 | 1221 | 0.320 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 490 | 0.310 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 848 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1131 | 0.290 |
Why?
|
| Treatment Outcome | 5 | 2024 | 8273 | 0.290 |
Why?
|
| Quality of Life | 2 | 2024 | 1682 | 0.240 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 122 | 0.230 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2024 | 24 | 0.230 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 2370 | 0.230 |
Why?
|
| Mass Spectrometry | 1 | 2024 | 194 | 0.220 |
Why?
|
| Withholding Treatment | 1 | 2024 | 116 | 0.220 |
Why?
|
| Disease-Free Survival | 2 | 2023 | 1169 | 0.220 |
Why?
|
| CD3 Complex | 1 | 2023 | 134 | 0.210 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2655 | 0.210 |
Why?
|
| Hypercalcemia | 1 | 2023 | 63 | 0.210 |
Why?
|
| Lymphoma, B-Cell | 1 | 2024 | 107 | 0.210 |
Why?
|
| Imides | 1 | 2022 | 26 | 0.210 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 52 | 0.200 |
Why?
|
| Bortezomib | 1 | 2022 | 80 | 0.200 |
Why?
|
| Melphalan | 1 | 2022 | 98 | 0.200 |
Why?
|
| Immunotherapy | 2 | 2025 | 698 | 0.200 |
Why?
|
| Bone Marrow | 1 | 2024 | 443 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 153 | 0.200 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 301 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 83 | 0.190 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 195 | 0.180 |
Why?
|
| Bone Marrow Examination | 1 | 2020 | 47 | 0.180 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 65 | 0.170 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.170 |
Why?
|
| Asparaginase | 1 | 2019 | 35 | 0.170 |
Why?
|
| Philadelphia Chromosome | 1 | 2019 | 42 | 0.170 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.160 |
Why?
|
| Health Care Surveys | 1 | 2020 | 281 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 98 | 0.160 |
Why?
|
| Standard of Care | 1 | 2019 | 65 | 0.160 |
Why?
|
| Reference Standards | 1 | 2019 | 144 | 0.160 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 386 | 0.160 |
Why?
|
| Allografts | 1 | 2019 | 184 | 0.160 |
Why?
|
| Sex Characteristics | 1 | 2020 | 328 | 0.150 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 155 | 0.150 |
Why?
|
| Palliative Care | 1 | 2019 | 264 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 360 | 0.140 |
Why?
|
| Sex Factors | 1 | 2020 | 1075 | 0.140 |
Why?
|
| Neoplasms | 2 | 2023 | 3065 | 0.140 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 995 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2020 | 872 | 0.140 |
Why?
|
| Leukocyte Count | 1 | 2017 | 224 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 952 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2023 | 9210 | 0.140 |
Why?
|
| Prognosis | 2 | 2023 | 3798 | 0.140 |
Why?
|
| Rituximab | 1 | 2017 | 117 | 0.130 |
Why?
|
| Time Factors | 3 | 2020 | 5359 | 0.130 |
Why?
|
| Patient Selection | 1 | 2019 | 682 | 0.130 |
Why?
|
| Disease Progression | 1 | 2020 | 1469 | 0.130 |
Why?
|
| Splanchnic Circulation | 1 | 2015 | 14 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 2018 | 0.130 |
Why?
|
| Body Weight | 1 | 2017 | 453 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 159 | 0.130 |
Why?
|
| Neutrophils | 1 | 2017 | 311 | 0.120 |
Why?
|
| Lymphocytes | 1 | 2017 | 468 | 0.120 |
Why?
|
| Serial Publications | 1 | 2014 | 2 | 0.120 |
Why?
|
| Journal Impact Factor | 1 | 2014 | 15 | 0.110 |
Why?
|
| Science | 1 | 2014 | 34 | 0.110 |
Why?
|
| Reproduction | 1 | 2014 | 199 | 0.100 |
Why?
|
| Prospective Studies | 1 | 2020 | 4331 | 0.100 |
Why?
|
| United States | 1 | 2024 | 7108 | 0.090 |
Why?
|
| Child | 1 | 2019 | 7244 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 598 | 0.070 |
Why?
|
| Risk Factors | 2 | 2015 | 5559 | 0.070 |
Why?
|
| Thalidomide | 1 | 2024 | 55 | 0.060 |
Why?
|
| Cell Transplantation | 1 | 2023 | 47 | 0.050 |
Why?
|
| Young Adult | 1 | 2015 | 6410 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 142 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 23 | 0.050 |
Why?
|
| Adolescent | 1 | 2015 | 9342 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 56 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2023 | 310 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 395 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 171 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 203 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 178 | 0.050 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 117 | 0.050 |
Why?
|
| Autografts | 1 | 2020 | 29 | 0.050 |
Why?
|
| Smoldering Multiple Myeloma | 1 | 2020 | 3 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 173 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 311 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 70 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 279 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 72 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 3021 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 216 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 205 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 193 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1352 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 476 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1134 | 0.030 |
Why?
|
| PubMed | 1 | 2014 | 13 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2767 | 0.030 |
Why?
|
| Phenotype | 1 | 2020 | 2458 | 0.030 |
Why?
|
| Sunlight | 1 | 2013 | 28 | 0.030 |
Why?
|
| Postmenopause | 1 | 2013 | 102 | 0.030 |
Why?
|
| Research | 1 | 2014 | 251 | 0.030 |
Why?
|
| Women's Health | 1 | 2013 | 103 | 0.030 |
Why?
|
| Vitamin D | 1 | 2013 | 269 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 2887 | 0.020 |
Why?
|